Skip to content

Osana Schlee

PhD student

My background

I completed my bachelor’s and master’s degrees in Neurobiology at the University of Amsterdam.

Following my master’s program, I gained valuable work experience at ZonMw, where I focused on medical research funding and collaborated with various stakeholders in the healthcare industry.

My projects

In 2023, I began my PhD at the Department of Immunology at Erasmus University Medical Centre in Rotterdam. My research focuses on investigating novel pathogenic antibodies in the paranodal regions associated with immune-mediated neuropathies. The goal of my project is to enhance diagnostic methods for detecting anti-paranodal antibodies and to assess the prevalence of these harmful autoantibodies in patients with Guillain-Barré Syndrome (GBS).

Additionally, I am exploring the role of B lymphocytes in the progression of chronic immune-mediated neuropathies, such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Autoimmune Nodopathy (AN). Through this research, we aim to improve the diagnostic process, clinical care, and treatment for patients with these conditions.

Research focus

My research focuses on GBS and CIDP.

A list of research articles

  • Detecting anti-paranodal antibodies

    • Study on GBS

    My research primarily focuses on investigating novel pathogenic antibodies in paranodal regions associated with immune-mediated neuropathies. The aim of my project is to improve diagnostic methods for detecting anti-paranodal antibodies and to determine the prevalence of these harmful autoantibodies in patients with Guillain-Barré Syndrome (GBS).

  • The role of B lymphocytes in the progression of chronic immune-mediated neuropathies

    • Study on CIDP

    In addition, I am studying the role of B lymphocytes in the progression of chronic immune-mediated neuropathies, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Autoimmune Nodopathy (AN). Through this research, we strive to enhance diagnostics, clinical care, and treatment options for patients affected by these conditions.